OpenLB
Open Library of Bioscience
Advanced Search
Cardiovascular therapeutics
2025;2025 8098173.

Impacts of Variants on Plasma Lipid Levels and the Risk of Early-Onset Coronary Artery Disease: A Systematic Review and Meta-Analysis.

Zhi Luo, Lingwei Lv
Author Information
  1. Zhi Luo: Department of Cardiology, Suining Central Hospital, Suining, Sichuan, China. ORCID
  2. Lingwei Lv: Department of Orthopedics, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China. ORCID
PMID: 40040886 DOI: 10.1155/cdr/8098173

Abstract

Recent studies have indicated that cluster of differentiation 36 (CD36) is closely linked to dyslipidemia and early-onset coronary artery disease (EOCAD). This study is aimed at investigating the impacts of gene variants on lipid profiles and EOCAD risk. PubMed, Cochrane Library, Central, CINAHL, and ClinicalTrials.gov were searched until June 15, 2024. In total, 25 studies (11,494 individuals) were included for the analysis. The A allele carriers of the rs1761667 variant had higher high-density lipoprotein cholesterol (HDL-C) levels and higher EOCAD risk than noncarriers. In contrast, the G allele carriers of the rs1049673 and rs3211956 variants had lower low-density lipoprotein cholesterol (LDL-C) levels and lower EOCAD risk than noncarriers. Subgroup analysis indicated that the antiatherosclerotic impact and reduced EOCAD risk were primarily observed in Chinese with rs1049673 and rs3211956. The rs1761667, rs1049673, and rs3211956 variants of the gene have significant impacts on lipid levels and may serve as genetic markers for the risk of EOCAD primarily in Chinese. The impacts of variants on EOCAD risk are mediated, at least partly, by dyslipidemia. Genetic screening of gene variants may be helpful for early intervention or prevention of EOCAD in individuals with high risk factors.

Keywords

CD36 dyslipidemia early-onset coronary artery disease genetic polymorphism

References

  1. Biometrics. 1994 Dec;50(4):1088-101 [PMID: 7786990]
  2. BMC Cardiovasc Disord. 2019 Jun 11;19(1):140 [PMID: 31185924]
  3. J Lipid Res. 2012 Mar;53(3):561-566 [PMID: 22210925]
  4. Am Heart J. 2002 Sep;144(3):449-55 [PMID: 12228781]
  5. PLoS One. 2010 Mar 26;5(3):e9906 [PMID: 20360851]
  6. J Biol Chem. 1996 Mar 29;271(13):7781-7 [PMID: 8631821]
  7. Br J Nutr. 2015 Apr 28;113(8):1330-7 [PMID: 25822988]
  8. Sci Rep. 2022 Apr 8;12(1):5916 [PMID: 35396566]
  9. Blood. 2011 Jun 9;117(23):6355-66 [PMID: 21478428]
  10. Scand J Clin Lab Invest. 2015 May;75(3):254-8 [PMID: 25723554]
  11. Trends Cardiovasc Med. 2003 May;13(4):136-41 [PMID: 12732446]
  12. Circulation. 2002 Dec 17;106(25):3143-421 [PMID: 12485966]
  13. J Biol Chem. 2007 Feb 23;282(8):5125-32 [PMID: 17164237]
  14. Kardiol Pol. 2016;74(6):570-5 [PMID: 26620683]
  15. J Exp Med. 1995 May 1;181(5):1857-62 [PMID: 7536797]
  16. Circulation. 2019 Jun 18;139(25):e1082-e1143 [PMID: 30586774]
  17. Prostaglandins Leukot Essent Fatty Acids. 2008 Jun;78(6):327-35 [PMID: 18550349]
  18. Gene. 2013 Dec 15;532(2):216-21 [PMID: 24055729]
  19. Hum Mol Genet. 2004 Oct 1;13(19):2197-205 [PMID: 15282206]
  20. Circulation. 2021 Jan 5;143(1):45-61 [PMID: 32988222]
  21. Eur Heart J. 2003 Feb;24(3):249-57 [PMID: 12590902]
  22. J Lipid Res. 2011 Apr;52(4):745-58 [PMID: 21217164]
  23. Transfusion. 2020 Apr;60(4):847-854 [PMID: 32129498]
  24. Int J Vitam Nutr Res. 2021 Sep;91(5-6):513-521 [PMID: 32419652]
  25. Int J Clin Exp Med. 2015 Sep 15;8(9):16149-57 [PMID: 26629128]
  26. PLoS Med. 2009 Jul 21;6(7):e1000100 [PMID: 19621070]
  27. Cardiovasc Diagn Ther. 2016 Apr;6(2):120-30 [PMID: 27054101]
  28. Contemp Clin Trials. 2007 Feb;28(2):105-14 [PMID: 16807131]
  29. J Clin Invest. 1995 Oct;96(4):1859-65 [PMID: 7560077]
  30. Hum Genet. 2014 Aug;133(8):985-95 [PMID: 24643644]
  31. Genet Test Mol Biomarkers. 2015 Mar;19(3):144-9 [PMID: 25565374]
  32. J Lipid Res. 2009 May;50(5):999-1011 [PMID: 18753675]
  33. Science. 1993 Nov 26;262(5138):1436-40 [PMID: 7504322]
  34. J Clin Invest. 2005 Aug;115(8):2192-201 [PMID: 16075060]
  35. Arch Pediatr. 2018 Apr;25(3):177-181 [PMID: 29576254]
  36. J Biol Chem. 1994 Jul 22;269(29):18985-91 [PMID: 7518447]
  37. J Lipid Res. 2016 Dec;57(12):2176-2184 [PMID: 27729386]
  38. Mol Med. 2007 May-Jun;13(5-6):288-96 [PMID: 17673938]
  39. PLoS One. 2012;7(12):e50198 [PMID: 23236364]
  40. Atherosclerosis. 1998 Jan;136(1):139-46 [PMID: 9544740]
  41. Nutrients. 2022 Jun 22;14(13): [PMID: 35807759]
  42. Cardiovasc Res. 2008 Apr 1;78(1):185-96 [PMID: 18065445]
  43. J Am Coll Cardiol. 2022 Mar 1;79(8):819-836 [PMID: 35210038]
  44. Br Med Bull. 2018 Jun 1;126(1):101-112 [PMID: 29534172]
  45. Saudi Med J. 2012 May;33(5):489-94 [PMID: 22588808]
  46. World J Diabetes. 2015 Jul 10;6(7):983-9 [PMID: 26185606]
  47. Blood Transfus. 2014 Oct;12(4):557-64 [PMID: 24960640]
  48. Toxicol Lett. 2022 Jun 15;363:1-10 [PMID: 35589016]
  49. Front Cardiovasc Med. 2021 Nov 23;8:768481 [PMID: 34888367]
  50. J Biol Chem. 1999 Sep 17;274(38):26761-6 [PMID: 10480880]
  51. J Lipid Res. 1998 Apr;39(4):777-88 [PMID: 9555943]
  52. Vox Sang. 2016 Apr;110(3):236-43 [PMID: 26528880]
  53. Cell Biochem Funct. 2010 Aug;28(6):480-9 [PMID: 20629037]
  54. Arterioscler Thromb Vasc Biol. 2000 Apr;20(4):1027-32 [PMID: 10764668]
  55. Arterioscler Thromb Vasc Biol. 2009 Oct;29(10):1481-7 [PMID: 19608973]
  56. Gene. 2020 Aug 30;753:144806 [PMID: 32461018]
  57. J Clin Invest. 2000 Apr;105(8):1049-56 [PMID: 10772649]
  58. BMC Med Genomics. 2022 Aug 29;15(1):186 [PMID: 36031603]
  59. Genet Mol Res. 2014 Sep 26;13(3):7708-17 [PMID: 25299084]
  60. Am J Clin Nutr. 2011 Mar;93(3):644-51 [PMID: 21228269]
  61. Obesity (Silver Spring). 2011 May;19(5):1004-9 [PMID: 20966915]
  62. Drugs. 2012 Mar 5;72(4):491-507 [PMID: 22356288]
  63. Genet Mol Res. 2012 Aug 13;11(3):2163-70 [PMID: 22869067]
  64. Arterioscler Thromb Vasc Biol. 2009 Jan;29(1):19-26 [PMID: 18948635]
  65. J Biol Chem. 1999 Jul 2;274(27):19055-62 [PMID: 10383407]
  66. J Clin Endocrinol Metab. 2018 May 1;103(5):1856-1866 [PMID: 29546316]
  67. Free Radic Biol Med. 2021 May 20;168:180-188 [PMID: 33775772]
  68. Atherosclerosis. 2002 Feb;160(2):433-40 [PMID: 11849668]
  69. Eur Heart J. 2020 Jan 1;41(1):111-188 [PMID: 31504418]
  70. Lancet. 2004 Sep 11-17;364(9438):937-52 [PMID: 15364185]
  71. Hum Mol Genet. 2011 Jan 1;20(1):193-201 [PMID: 20935172]
  72. J Nutrigenet Nutrigenomics. 2016;9(5-6):300-305 [PMID: 28237985]
  73. Braz J Med Biol Res. 2014 Oct;47(10):895-903 [PMID: 25118627]
  74. Thromb Res. 2015 May;135(5):951-7 [PMID: 25798958]
  75. Diabetol Metab Syndr. 2022 Aug 18;14(1):117 [PMID: 35982478]
  76. World J Hepatol. 2016 Sep 8;8(25):1067-74 [PMID: 27660673]
  77. Gene. 2013 Nov 1;530(1):134-7 [PMID: 23856131]

MeSH Term

Humans
CD36 Antigens
Coronary Artery Disease
Genetic Predisposition to Disease
Age of Onset
Risk Assessment
Male
Phenotype
Female
Polymorphism, Single Nucleotide
Dyslipidemias
Middle Aged
Risk Factors
Lipids
Adult
Cholesterol, HDL
Cholesterol, LDL

Chemicals

CD36 Antigens
CD36 protein, human
Lipids
Cholesterol, HDL
Cholesterol, LDL
Systematic Review Meta-Analysis Journal Article

Word Cloud

Created with Highcharts 10.0.0EOCADriskvariantsdyslipidemiaimpactsgenelevelsrs1049673rs3211956studiesindicatedCD36early-onsetcoronaryarterydiseaselipidindividualsanalysisallelecarriersrs1761667higherlipoproteincholesterolnoncarrierslowerprimarilyChinesemaygeneticRecentclusterdifferentiation36closelylinkedstudyaimedinvestigatingprofilesPubMedCochraneLibraryCentralCINAHLClinicalTrialsgovsearchedJune152024total2511494includedvarianthigh-densityHDL-CcontrastGlow-densityLDL-CSubgroupantiatheroscleroticimpactreducedobservedsignificantservemarkersmediatedleastpartlyGeneticscreeninghelpfulearlyinterventionpreventionhighfactorsImpactsVariantsPlasmaLipidLevelsRiskEarly-OnsetCoronaryArteryDisease:SystematicReviewMeta-Analysispolymorphism

Similar Articles

Cited By

No available data.